BMJ published the results of a multi-center randomized and placebo-controlled double-blind phase 3 trial evaluating the efficacy of oral methylcobalamin (vitamin B12) to help prevent hand-foot syndrome among women receiving capecitabine treatment for human epidermal growth factor receptor 2 (HER2) negative early breast cancer. A range of 29–73% of women receiving treatment with capecitabine experience hand-foot syndrome, characterized by redness, pain, swelling, and dysesthesia in the palms...
